MetaCap

Fate Therapeutics (FATE) vs LENZ Therapeutics (LENZ)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fate Therapeutics (FATE) has outperformed LENZ Therapeutics (LENZ) over the past year, losing 10.8% versus a loss of 90.0%. Over five years, LENZ leads with a -95.6% price change compared with -98.3% for FATE. Fate Therapeutics is the larger company by market cap ($111.8 million vs $93.2 million), about 1.2 times the size.

LENZ Therapeutics converts more of its revenue into profit, with a net margin of -430.3% versus -2051.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FATE-10.78%LENZ-89.97%
+217%+56%-105%
Nov 21, 20251 yearNov 20, 2026
FATE-98.36%LENZ-96.18%
+21%-42%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FATE versus LENZ key metrics
MetricFATELENZ
Share price$0.919$2.97
Market cap$111.82M$93.16M
1-day change-9.01%-11.23%
YTD return-6.22%-81.47%
1-year return-10.78%-89.97%
5-year return-98.25%-95.57%
EPS (TTM)$-1.03$-4.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.65M$19.09M
Revenue growth (YoY)-51.24%—
Net income (latest FY)$-136.31M$-82.13M
Gross margin—97.81%
Operating margin-2222.45%-477.46%
Net margin-2051.08%-430.25%
52-week high$3.23$32.13
52-week low$0.90$2.80
Distance from 52-week high-71.55%-90.77%
Analyst consensusbuynone
Avg. price target upside+522.42%+400.17%
Average volume1.53M892.30K
Shares outstanding121.67M31.42M
Employees16140
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FATE has outperformed LENZ by 79.2 percentage points over the past year.
  • LENZ Therapeutics is more profitable, keeping -430.3 cents of every revenue dollar as net income versus -2051.1 cents for Fate Therapeutics.

About Fate Therapeutics

FATE stock →

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees

About LENZ Therapeutics

LENZ stock →

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees

FATE vs LENZ FAQ

Which is bigger, Fate Therapeutics or LENZ Therapeutics?

Fate Therapeutics (FATE) is larger, with a market capitalization of $111.82M compared with $93.16M for LENZ Therapeutics (LENZ).

Which stock has performed better over the past year, FATE or LENZ?

FATE returned -10.78% over the past 12 months, compared with -89.97% for LENZ (price return, excluding dividends). Past performance does not predict future results.

Are Fate Therapeutics and LENZ Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons